BRAF and Miyoshi myopathy: NRAS, KRAS, BRAF, TP53, FAM46C, DIS3, CCND1, and other genes, are thought to contribute to the pathogenesis of MM and are clinical biomarkers for the selection of targeted therapeutic strategies.